Dr. Kasi on the Application of Pharmacogenomics in CRC

Video

In Partnership With:

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Genetic testing is underutilized in CRC, says Kasi, although it can help guide treatment decisions based on the mutations or variations a patient may present with. For patients with CRC, it is known that certain genes metabolize 5-fluorouracil or capecitabine. Moreover, physicians are familiar with the drugs that metabolize irinotecan chemotherapy. Historical analyses have shown that these patients fare worse in terms of toxicity when they receive chemotherapy and harbor an aberration in one of these genes, he adds.

Incorporating this testing into practice is viable, says Kasi. Now, test results come back within 3 to 5 days which enables physicians to make treatment decisions in real-time. Additionally, there are guidelines that show how much chemotherapy a patient should be given if they have an aberration in a certain gene.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute